BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 17625370)

  • 21. Challenging the platinum combinations: docetaxel (Taxotere) combined with gemcitabine or vinorelbine in non-small cell lung cancer.
    Georgoulias V; Scagliotti G; Miller V; Eckardt J; Douillard JY; Manegold C
    Semin Oncol; 2001 Feb; 28(1 Suppl 2):15-21. PubMed ID: 11284620
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients.
    Wang Y; Wen L; Zhao SH; Ai ZH; Guo JZ; Liu WC
    Lung Cancer; 2013 Feb; 79(2):173-9. PubMed ID: 23177020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Second-Line docetaxel and gemcitabine combination chemotherapy in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: a phase II trial.
    Tas F; Demir C; Camlica H; Ustuner Z; Topuz E
    Med Oncol; 2004; 21(3):233-40. PubMed ID: 15456950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anticancer drug clustering in lung cancer based on gene expression profiles and sensitivity database.
    Gemma A; Li C; Sugiyama Y; Matsuda K; Seike Y; Kosaihira S; Minegishi Y; Noro R; Nara M; Seike M; Yoshimura A; Shionoya A; Kawakami A; Ogawa N; Uesaka H; Kudoh S
    BMC Cancer; 2006 Jun; 6():174. PubMed ID: 16813650
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale for non-platinum chemotherapy in advanced NSCLC.
    Murren JR
    Oncology (Williston Park); 2001 Jul; 15(7 Suppl 8):29-34. PubMed ID: 11497229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lung cancer: therapeutic options for stage IV and recurrent NSCLC.
    Calvo AR; Belani CP
    Cancer Treat Res; 2001; 105():189-227. PubMed ID: 11224988
    [No Abstract]   [Full Text] [Related]  

  • 27. Efficacy of cancer chemotherapy in relation to the pretreatment number of lymphocytes in patients with metastatic solid tumors.
    Lissoni P; Brivio F; Fumagalli L; Messina G; Ghezzi V; Frontini L; Giani L; Vaghi M; Ardizzoia A; Gardani GS
    Int J Biol Markers; 2004; 19(2):135-40. PubMed ID: 15255546
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial.
    Georgoulias V; Ardavanis A; Tsiafaki X; Agelidou A; Mixalopoulou P; Anagnostopoulou O; Ziotopoulos P; Toubis M; Syrigos K; Samaras N; Polyzos A; Christou A; Kakolyris S; Kouroussis C; Androulakis N; Samonis G; Chatzidaki D
    J Clin Oncol; 2005 May; 23(13):2937-45. PubMed ID: 15728228
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent advances in the chemotherapy of non-small cell lung cancer.
    Inoue A; Saijo N
    Jpn J Clin Oncol; 2001 Jul; 31(7):299-304. PubMed ID: 11518741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin.
    Pujol JL; Breton JL; Gervais R; Rebattu P; Depierre A; Morère JF; Milleron B; Debieuvre D; Castéra D; Souquet PJ; Moro-Sibilot D; Lemarié E; Kessler R; Janicot H; Braun D; Spaeth D; Quantin X; Clary C
    Ann Oncol; 2005 Apr; 16(4):602-10. PubMed ID: 15741225
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A landmark point analysis with cytotoxic agents for advanced NSCLC.
    Yamamoto N; Nambu Y; Fujimoto T; Koshiji M
    J Thorac Oncol; 2009 Jun; 4(6):697-701. PubMed ID: 19318995
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topoisomerase I inhibitors combination chemotherapy in non-small cell lung cancer.
    Tumolo S; Toffoli G; Saracchini S; Lo Re G; Bruschi G; Boccieri MG
    Lung Cancer; 2001 Dec; 34 Suppl 4():S37-46. PubMed ID: 11742701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02).
    Hosoe S; Komuta K; Shibata K; Harada H; Iwamoto Y; Ohsaki Y; Morioka T; Origasa H; Fukushima M; Furuse K; Kawahara M
    Br J Cancer; 2003 Feb; 88(3):342-7. PubMed ID: 12569374
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
    Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
    J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternating doublets: establishing the optimal multifractionated dosing schedule to administer docetaxel, cisplatin, gemcitabine, and vinorelbine in combination.
    Lokich J; Anderson N; Coco F
    Cancer Invest; 2003; 21(6):830-6. PubMed ID: 14735686
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Challenging the platinum combinations in the chemotherapy of NSCLC.
    Douillard JY; Eckardt J; Scagliotti GV
    Lung Cancer; 2002 Dec; 38 Suppl 4():21-8. PubMed ID: 12480191
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network.
    Hainsworth JD; Burris HA; Billings FT; Bradof JE; Baker M; Greco FA
    Cancer; 2001 Nov; 92(9):2391-8. PubMed ID: 11745295
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination effects of cisplatin, vinorelbine and irinotecan in non-small-cell lung cancer cell lines in vitro.
    Mogi H; Hasegawa Y; Watanabe A; Nomura F; Saka H; Shimokata K
    Cancer Chemother Pharmacol; 1997; 39(3):199-204. PubMed ID: 8996520
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sequential administration of vinorelbine plus cisplatin and bevacizumab followed by docetaxel plus gemcitabine and bevacizumab compared to docetaxel plus cisplatin and bevacizumab regimen as first-line therapy for advanced or metastatic non-squamous non-small cell lung cancer: A multicenter randomized phase II trial of the Hellenic Oncology Research Group (HORG).
    Kotsakis A; Kentepozidis N; Emmanouilidis Ch; Polyzos A; Agelidou A; Vaslamatzis M; Chandrinos V; Agelaki S; Vamvakas L; Kalbakis K; Katsaounis P; Stoltidis D; Nintos G; Hatzidaki D; Vetsika EK; Mavroudis D; Georgoulias V
    Lung Cancer; 2015 Apr; 88(1):57-62. PubMed ID: 25662596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does the sequence of gemcitabine and vinorelbine affect their efficacy in non-small cell lung cancer in vitro?
    De Luca A; Grassii M; Maiello MR; Di Maio M; Mancino M; De Maio E; Gridelli C; Perrone F; Normanno N
    Anticancer Res; 2004; 24(5A):2985-9. PubMed ID: 15517905
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.